Bausch Health Companies Inc. (BHC)

Bausch Health Companies Inc. is trading at $6.23, down 4.08% on the session. The 50 day average sits at $6.16 and the 200 day at $5.73, which puts the stock in a uptrend. RSI is at 61.8, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $6.14 with resistance near $6.35, so that band frames the current range. Average daily movement is roughly $0.26, or about 4.1% of the share price, which is what any stop placement has to allow for. The overall health score of 81 out of 100 combines a trend score of 84, momentum of 85 and a risk score of 71.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.